Moderna, Inc. (MRNA)
- Previous Close
106.18 - Open
106.18 - Bid 107.97 x 200
- Ask 108.04 x 200
- Day's Range
105.39 - 108.18 - 52 Week Range
62.55 - 142.79 - Volume
2,239,372 - Avg. Volume
3,759,649 - Market Cap (intraday)
41.34B - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-12.33 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
123.36
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA
Performance Overview: MRNA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA
Valuation Measures
Market Cap
41.34B
Enterprise Value
33.98B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.11
Price/Book (mrq)
2.98
Enterprise Value/Revenue
5.03
Enterprise Value/EBITDA
-10.35
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.84%
Return on Assets (ttm)
-11.96%
Return on Equity (ttm)
-28.59%
Revenue (ttm)
6.85B
Net Income Avi to Common (ttm)
-4.71B
Diluted EPS (ttm)
-12.33
Balance Sheet and Cash Flow
Total Cash (mrq)
8.6B
Total Debt/Equity (mrq)
8.97%
Levered Free Cash Flow (ttm)
-2.38B
Research Analysis: MRNA
Company Insights: MRNA
MRNA does not have Company Insights